Business Wire - January 31, 2000
Following HIV-1 infection, the number of CD8+ T lymphocytes (CTL) increases substantially. These cells include a cell population, expanded in HIV infection, that targets both infected and uninfected CD4+ lymphocytes. Associated depletion of uninfected CD4+ cells is characteristic of disease progression. Therefore, modulation of the CTL activated in HIV infected individuals may be beneficial.
Dr. Michael Grant, a member of Immune Network's Scientific Advisory Board, led this study. Dr. Grant is presently assistant professor of Immunology in the faculty of Medicine at Memorial University where he is continuing his studies on immune system function and HIV. Dr. Grant is the recipient of a number of research awards and is a national AIDS scholar.
Immune Network's Commercial Director, Ron Kertesz, said, "The results of this recent study indicate that 1F7 selectively inhibits the CTL mediated destruction of uninfected CD4+ cells. This is a very significant finding which further strengthens the potential of this antibody to become an effective AIDS therapeutic.
"Simplistically put, what we have here is some positive indication that our anti-AIDS drug candidate may help reduce the number of 'killer' T cells that destroy uninfected 'helper T cells.' This is in addition to previous evidence indicating increased antibody production against mutated forms of the virus."
The mission of Immune Network Research Ltd. is to utilize its expertise and world class scientific network to identify outstanding commercial opportunities for new drug treatments, rapidly complete critical milestones in their development and realize a return on the company's investment via licenses, alliances or spin-offs.
Allen Bain, President & C.E.O. IMMUNE NETWORK RESEARCH LTD.
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the value of this project to Immune Network, contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties. Although Immune Network has used best efforts to be accurate in making those forward-looking statements, it is possible that the assumptions made by management of Immune Network may not materialize. In addition, other important factors which could cause results to differ materially include the following: economic conditions in the pharmaceutical, biotechnology and internet industries; risks associated with acquisitions; loss of large contracts; competition within the industries; the ability to attract and retain key personnel; and the risk factors set forth from time to time in the SEC filings for Immune Network, copies of which are available upon request from Immune Network's investor relations department.
Note to Editors: The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
CONTACT: Immune Network Research Ltd. Ron Kertesz, 604/222-5541 rkertesz@immunenetwork.com www.immunenetwork.com
000131
BW000109
Copyright © 2000 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .